Evidence map›Paper›PMID 35740493›Full record

ArticleCancers2022

APOBEC Alteration Contributes to Tumor Growth and Immune Escape in Pan-Cancer.

Honghong Guo, Ling Zhu, Lu Huang, Zhen Sun, Hui Zhang, Baoting Nong, Yuanyan Xiong

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Deaminase Modulation Driving a New Era in Drug Development.International journal of molecular sciences · 2025
    Review
  7. Article
  8. Review
  9. Clinical Implications of APOBEC3-Mediated Mutagenesis in Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Review
  10. APOBECs: Our fickle friends?PLoS pathogens · 2023
    Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Honghong GuoKey Laboratory of Gene Engineering, Ministry of Education, Institute of Healthy Aging Research, School of Life Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Ling ZhuKey Laboratory of Gene Engineering, Ministry of Education, Institute of Healthy Aging Research, School of Life Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Lu HuangKey Laboratory of Gene Engineering, Ministry of Education, Institute of Healthy Aging Research, School of Life Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Zhen SunKey Laboratory of Gene Engineering, Ministry of Education, Institute of Healthy Aging Research, School of Life Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Hui ZhangKey Laboratory of Gene Engineering, Ministry of Education, Institute of Healthy Aging Research, School of Life Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Baoting NongKey Laboratory of Gene Engineering, Ministry of Education, Institute of Healthy Aging Research, School of Life Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Yuanyan XiongKey Laboratory of Gene Engineering, Ministry of Education, Institute of Healthy Aging Research, School of Life Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Sun Yat-sen University · CN

Funding

National Natural Science Foundation of China 31871323
6 · The paper itself

Abstract

The accumulating evidence demonstrates that the apolipoprotein B mRNA editing enzyme catalytic polypeptide-like (APOBEC), DNA-editing protein plays an important role in the molecular pathogenesis of cancer. In particular, the APOBEC3 family was shown to induce tumor mutations by an aberrant DNA editing mechanism. However, knowledge regarding the reconstitution of the APOBEC family genes across cancer types is still lacking. Here, we systematically analyzed the molecular alterations, immuno-oncological features, and clinical relevance of the APOBEC family in pan-cancer. We found that APOBEC genes were widely and significantly differentially expressed between normal and cancer samples in 16 cancer types, and that their expression levels are significantly correlated with the prognostic value in 17 cancer types. Moreover, two patterns of APOBEC-mediated stratification with distinct immune characteristics were identified in different cancer types, respectively. In ACC, for example, the first pattern of APOBEC-mediated stratification was closely correlated with the phenotype of immune activation, which was characterized by a high immune score, increased infiltration of CD8 T cells, and higher survival. The other pattern of APOBEC-mediated stratification was closely correlated with the low-infiltration immune phenotype, which was characterized by a low immune score, lack of effective immune infiltration, and poorer survival. Further, we found the APOBEC-mediated pattern with low-infiltration immune was also highly associated with the advanced tumor subtype and the CIMP-high tumor subtype (CpG island hypermethylation). Patients with the APOBEC-mediated pattern with immune activation were more likely to have therapeutic advantages in ICB (immunological checkpoint blockade) treatment. Overall, our results provide a valuable resource that will be useful in guiding oncologic and therapeutic analyses of the role of APOBEC family in cancer.

Indexed as

APOBECclinical relevancegenetic alterationsimmunotherapypan-cancersurvivaltumor microenvironment

Identifiers

PMID35740493
PMCPMC9221198
OpenAlexW4281746694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.